ESMO 2023 Conference Review – Lung Cancer Focus

In this review:
  -  CheckMate 77T: Nivolumab
  -  KEYNOTE-671: Pembrolizumab
  -  CheckMate 861: Nivolumab and PD-L1 expression
  -  TROPION-Lung01: Datopotamab deruxtecan
  -  MARIPOSA: Amivantamab vs osimertinib
  -  MARIPOSA-2: Amivantamab post osimertinib
  -  PAPILLON: Amivantamab
  -  LIBRETTO-431: Selpercatinib
  -  ALINA: Alectinib

Please login below to download this issue (PDF)

Subscribe